Untargeted lipidomics reveals specific lipid abnormalities in systemic lupus erythematosus

作者：Yingzhuo Wang, Feng Guo, Yunke Guo, Yan Lu, Wei Ji, Lili Lin, Wenjun Chen, Tingting Xu, Deshun Kong, Qiuxiang Shen, Youjuan Zhu, Ping Liu, Jinfeng Su, Lu Wang, Yuhua Li, Pan Gao, Jinjun Shan, Shijia Liu · 发表于：Clinical and Experimental Rheumatology · 年份：2021 · DOI：10.55563/clinexprheumatol/ye2ua5 · 被引用次数：11 · 研究领域：Sphingolipid Metabolism and Signaling、Liver Disease Diagnosis and Treatment、Systemic Lupus Erythematosus Research

To identify potential lipid biomarkers by studying changes in the blood lipid profile of patients with systemic lupus erythematosus (SLE) using lipidomics.Serum samples were collected from 115 SLE patients and 115 age- and sex-matched healthy controls (HCs). Lipid profiles were assessed using ultrahigh-performance liquid chromatography coupled with Q Exactive spectrometry, and possible lipid biomarkers were screened and evaluated by univariate and multivariate analyses.Metabolic phenotypes related to SLE disease activity index (SLEDAI) scores were detected in the serum of SLE patients, and these phenotypes indicated the activity of the disease. Alterations in energy metabolism, fatty acid metabolism and other pathways were observed in patients with SLE. Phosphatidylethanolamine (16:0/18:2), lysophosphatidylethanolamine (18:0), and acylcarnitine (11:0) can be used as biomarkers for the clinical diagnosis of SLE, and receiver operating characteristic (ROC) analysis indicated their effectiveness in diagnosing this disease.Our study identified serum biomarkers related to disease activity in patients with SLE, providing a basis for its clinical diagnosis.